NCT04855799View on ClinicalTrials.gov

GI Permeability Change in Response to Aquamin®

PHASE2CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

November 2, 2021

Primary Completion Date

March 11, 2024

Study Completion Date

March 25, 2024

Conditions
Ulcerative ColitisHealthyIrritable Bowel Syndrome With Diarrhea
Interventions
DRUG

Aquamin

Participants will take a 90-day supply of Aquamin®, 4 capsules per day; 2 to be taken in the morning and 2 in the evening (containing approximately 800 mg calcium/day).

Trial Locations (1)

48109

University of Michigan Hospital, Ann Arbor

All Listed Sponsors
lead

James Varani

OTHER

NCT04855799 - GI Permeability Change in Response to Aquamin® | Biotech Hunter | Biotech Hunter